Rabies

Bavarian Nordic Receives U.S. and EU Approvals of its Fill and Finish Vaccine Manufacturing Facility

Retrieved on: 
Wednesday, July 27, 2022
PAI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Rabies, Committee, Food, Johnson & Johnson, Danish Medicines Agency, Janssen Pharmaceuticals, Tick-borne encephalitis, CEO, Danish, Bavarian Nordic, EMA, European Directive on Traditional Herbal Medicinal Products, Government, Monkeypox, Immune system, COVID-19, Public health, OMX, Achievement, Review, European Medicines Agency, CHMP, FDA, Company, Committee for Medicinal Products for Human Use, Smallpox, WHO, Vaccine, Pharmaceutical industry, EU

An expedited pre-approval inspection (PAI) was conducted by the U.S. Food and Drug Administration (FDA) at the facility at the beginning of July 2022.

Key Points: 
  • An expedited pre-approval inspection (PAI) was conducted by the U.S. Food and Drug Administration (FDA) at the facility at the beginning of July 2022.
  • The inspection included the final drug production of JYNNEOS, which was previously performed at a contract manufacturer.
  • The inspection was successfully completed with no observations made, which has led to the approval of Bavarian Nordic as the new drug product manufacturer of JYNNEOS.
  • Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines.

PharmaJet Presents Latest Research Showing Benefits of Needle-free at mRNA-Based Therapeutics Summit

Retrieved on: 
Tuesday, July 19, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Medical Devices, Infectious Diseases, Stratis, N/S, Research, Public health, LNP, University, Rabies, USAMRIID, Method, LinkedIn, RNA transfection, WHO, Infection, Injection, Safety, DVM, Therapy, Review, System, Lancet, Rabbit, United States Army Medical Research Institute of Infectious Diseases, Certification, Use, Sue VandeWoude, Smallpox, Vaccination, Nucleic acid, COVID-19, ID, PQS, CE marking, Veni, vidi, vici, Doctor of Philosophy, IM, U.S. FDA, Vaccine, TROPI

PharmaJet , a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022.

Key Points: 
  • PharmaJet , a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022.
  • The presentation, entitled Advances in mRNA vaccines and therapeutics delivery with PharmaJet Needle-free Injection Systems, will be presented by Carmen Ledesma-Feliciano, DVM, PhD, DACLAM, Clinical Device Specialist at PharmaJet.
  • PharmaJet Needle-free Injection Systems (NFIS) are increasingly being incorporated into preclinical and clinical studies across multiple nucleic acid vaccine and therapeutic development programs.
  • This presentationwill highlight several partner studies that show the benefits of the PharmaJet NFIS including improved immunogenicity, dose-reduction, lower cost, and better patient and healthcare worker experience.

U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic

Retrieved on: 
Friday, July 15, 2022
Office of Inspector General, U.S. Department of Health and Human Services, Johnson & Johnson, Office of the Assistant Secretary for Preparedness and Response, Tick-borne encephalitis, Rabies, Government, CEO, Smallpox vaccine, Monkeypox, Department, Janssen Pharmaceuticals, Biomedical Advanced Research and Development Authority, OMX, Forward-looking statement, Immune system, Assistant, DKK, Goal, Smallpox, Development, Bavarian Nordic, COVID-19, Company, United States Department of Health and Human Services, U.S. Department of Defense Strategy for Operating in Cyberspace, FDA, Vaccine, Contract manufacturing organization, Contract, Vaccinia, EBITDA, BARDA, Pharmaceutical industry

The new order follows two previous orders from BARDA in June and July 2022 for 500,000 and 2.5 million doses respectively which, together with an order from BARDA in 2020 for 1.4 million doses, will bring the total deliveries in 2022 and 2023 to nearly 7 million doses.

Key Points: 
  • The new order follows two previous orders from BARDA in June and July 2022 for 500,000 and 2.5 million doses respectively which, together with an order from BARDA in 2020 for 1.4 million doses, will bring the total deliveries in 2022 and 2023 to nearly 7 million doses.
  • Paul Chaplin, President and CEO of Bavarian Nordic said: Expanding our manufacturing capabilities into the United States allows Bavarian Nordic to deliver more monkeypox vaccines to meet the immediate worldwide demand for JYNNEOS.
  • Under this contract Bavarian Nordic has produced bulk vaccine, corresponding to approximately 13 million doses for future delivery.
  • Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines.

mRNA Platform Global Market Report 2022: Featuring Key Players BioNTech, Moderna, CureVac & Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 13, 2022
Pharmaceutical, Health, COVID-19, COVID-19, Tissue, Gene, BioNTech, Program, Incidence, CureVac, Pancreas, Lung, Risk, Influenza, Prostate, Kidney cancer, Malaria, Degenerative disease, Heart, Brain, Rabies, Breast, Protein, RNA transfection, Cancer, Lists of diseases, HIV, Skin, Virus, Liver, Neoplasm, Melanoma, Research, Immune system, Growth, Infection, Vaccine

The "mRNA Platform - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "mRNA Platform - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Currently, of the total 44 ongoing clinical trials of mRNA vaccines, 23 of them are aimed at infectious diseases.
  • Cancer research has used mRNA platform to trigger the immune system to target specific cancer cells.
  • mRNA can be used as protein replacement therapy to treat diseases caused by a lack of protein, or by defective proteins.

Worldwide Integrated Pest Management Industry to 2027 - by Pest Type, Control Method, Application and Geography - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 12, 2022
Chemicals, Plastics, Agriculture, Natural Resources, Manufacturing, Knowledge, Method, IPM, Eating, Food safety, Food and Agriculture Organization, United Nations, Food security, Tick, Solution, Allergy, Awareness, Food, Environment, Mycosis, Integrated pest management, Agriculture, COVID, Globe, Plant, Government, COVID-19, Bacteria, Rabies, Zika virus, Population, Climate change, Invertebrate, Lyme disease, Virus, Cockroach, Pest control, Prion, Vertebrate, Growth, Farmer, Coronavirus, Conditional sentence, Risk management, Poultry, Zika fever

Pest management has turned out to be an efficient solution to safely procure the crops by efficiently handling the pest attacks.

Key Points: 
  • Pest management has turned out to be an efficient solution to safely procure the crops by efficiently handling the pest attacks.
  • With the rise in technological advancements and increasing government expenditure, integrated pest management has become quite necessary, especially regarding food safety.
  • Impact of COVID-19 Pandemic on the Integrated Pest Management Market:
    With the outburst of the coronavirus pandemic across the globe, integrated pest management, especially in the agriculture sector, suffered negatively.
  • However, with the increase in pest control management and hygiene practices, especially after the COVID, the demand for integrated pest management is expected to increase in the future.

U.S. Government Orders Additional Monkeypox Vaccines from Bavarian Nordic

Retrieved on: 
Friday, July 1, 2022
Department, United States Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, FDA, Assistant, CEO, OMX, Biomedical Advanced Research and Development Authority, Government, Johnson & Johnson, COVID-19, Company, Goal, Forward-looking statement, Vaccinia, Bavarian Nordic, Development, Immune system, Contract, Office of Inspector General, U.S. Department of Health and Human Services, Monkeypox, Food, Risk, Tick-borne encephalitis, U.S. Department of Defense Strategy for Operating in Cyberspace, Janssen Pharmaceuticals, Smallpox, Smallpox vaccine, BARDA, Rabies, Infection, Vaccine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Contract manufacturing organization, Pharmaceutical industry

The doses will be manufactured from bulk vaccine already manufactured and invoiced under previous contracts with BARDA and currently stored at Bavarian Nordic.

Key Points: 
  • The doses will be manufactured from bulk vaccine already manufactured and invoiced under previous contracts with BARDA and currently stored at Bavarian Nordic.
  • Under this contract Bavarian Nordic has produced bulk vaccine, corresponding to approximately 13 million doses for future delivery.
  • Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines.
  • The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe.

Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors

Retrieved on: 
Thursday, June 16, 2022
Brandeis University, Biotechnology, Review, Securities Exchange Act of 1934, MBA, OTC Markets Group, Vaccine, Technology, Degenerative disease, CD56, Columbia Business School, Historical annual reformulations of the influenza vaccine, Company, Coronavirus Scientific Advisory Board (Turkey), OTC, AMD, Neuro, List of Nobel laureates, Metformin, Financial compensation, Securities Act of 1933, University, Partnership, Infection, Board of directors, Rabies, Board, Neoplasm, GLOBE, Judgement, Security (finance), Pharmaceutical industry, Economics

Boca Raton, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee.

Key Points: 
  • In addition to being a founder, Mr. Zaslow also served as a director and president, over a period of fifteen years.
  • Zaslow earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School.
  • Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases.
  • Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease.

Bavarian Nordic Receives an Additional Order for JYNNEOS Smallpox and Monkeypox Vaccine from the U.S. Government

Retrieved on: 
Friday, June 10, 2022
Bavarian Nordic, Janssen Pharmaceuticals, Goal, Smallpox, Company, Research, HHS, Johnson & Johnson, United States Department of Health and Human Services, EBITDA, Monkeypox, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, Smallpox vaccine, Tick-borne encephalitis, Contract, RSV, Forward-looking statement, CEO, Office of Inspector General, U.S. Department of Health and Human Services, Government, U.S. Department of Defense Strategy for Operating in Cyberspace, Investment, Respiratory syncytial virus, Vaccinia, Vaccine, FDA, Development, Rabies, Assistant, BARDA, COVID-19, Immune system, Department, Futures contract, OMX, USD, DKK, Pharmaceutical industry

The doses will be manufactured from bulk vaccine already manufactured and invoiced under previous contracts with BARDA and currently stored at Bavarian Nordic.

Key Points: 
  • The doses will be manufactured from bulk vaccine already manufactured and invoiced under previous contracts with BARDA and currently stored at Bavarian Nordic.
  • The majority of this bulk, however, will be converted to approximately 13 million freeze-dried doses of JYNNEOS during 2023-2025.
  • We are pleased to support BARDA in their continued efforts to build and strengthen the national preparedness against smallpox and monkeypox.
  • The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe.

Bavarian Nordic Enters a New Multi-Year Vaccine Contract with the Government of Canada

Retrieved on: 
Tuesday, June 7, 2022
Vaccination, Modified vaccinia Ankara, Janssen Pharmaceuticals, Goal, Smallpox, Immunodeficiency, Johnson & Johnson, Immunization, Public Health Agency of Canada, Monkeypox, Smallpox vaccine, Ageing, Contract, Tick-borne encephalitis, Forward-looking statement, Government, OMX, Vaccine, FDA, Rabies, COVID-19, Immune system, Population, Royal commission, European Commission, Public Health Agency, Government of Canada, PHAC, Bavarian Nordic

The non-replicating smallpox vaccine is also approved for use against monkeypox in Canada as the only territory other than the USA.

Key Points: 
  • The non-replicating smallpox vaccine is also approved for use against monkeypox in Canada as the only territory other than the USA.
  • Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: We are pleased to extend our collaboration with the Government of Canada.
  • We applaud the Government of Canada for their long-term planning, allowing us to execute on this contract in a timely manner.
  • The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe.

Veterinary Vaccines Market to Hit US$ ~13.09 billion by 2031 | Exclusive Report by Growth Plus Reports

Retrieved on: 
Tuesday, May 31, 2022
Poultry, Infection, Livestock, Vaccine, APPA, Health, US, Transport, Ownership, Merck, American Pet Products Association, Vaccination, Rabies, Zoonosis, Intention, Awareness, Government, Bee, Human, Row, Animal, Growth, Aquaculture, Disease, Pet

The global veterinary vaccines market has been analyzed from three different perspectives Animal Type, Vaccine Type, and Region.

Key Points: 
  • The global veterinary vaccines market has been analyzed from three different perspectives Animal Type, Vaccine Type, and Region.
  • However, the high costs associated with vaccine development and storage & handling remain a major concern for the growth of the veterinary vaccines market.
  • The global veterinary vaccines market has been segmented majorly into two distinct categories depending on animal type, viz.
  • The companion animals segment is expected to be the fastest growing segment in the veterinary vaccines market.